Market Update (NASDAQ:BIIB): Biogen 2015 Revenues Increase 11% to $10.8 Billion

[Business Wire] – Biogen Inc. today reported full year and fourth quarter 2015 results, including full year revenues of $10.8 billion, an 11% increase versus 2014. Full year 2015 Non-GAAP diluted earnings per share were $17.01, an increase of 23% versus 2014. Read more on this. Biogen Inc. (BIIB) , valued at $60.41B, began trading this morning at $275.04. During today’s session, BIIB traded between $270.44 to $280.00 with the price of the stock fluctuating between $254.00 to $480.18 over the last 52 weeks. BIIB shares are currently priced at 15.65x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s -1.49x earnings multiple. In a review of the consensus earnings estimate this quarter, 21 sell-side analysts are looking at $4.08 per share, which would be $0.01 worse than the year-ago quarter and a $0.03 sequential increase. Investors should also note that the full-year EPS estimate of $16.60 is a $2.77 better when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $2.71 Billion. If reported, that would be a 2.65% increase over the year-ago quarter. Recently, Credit Suisse Initiated BIIB at Neutral (Jan 20, 2016). Previously, Standpoint Research Initiated BIIB at to Buy. When considering if the stock is under or overvalued, the average price target is $363.31, which is 32.09% above where the stock opened this morning. See more in (NASDAQ:BIIB) Similar Articles: Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen, the ALS Association and Columbia University Medical Center Collaborate to Drive Understanding of Genetic Influence in ALS Market Update: Biogen Idec Inc (NASDAQ:BIIB) – SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Biogen Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws — BIIB Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – BIIB INVESTORS: The Law Offices of Howard G. Smith Announces An Investigation On Behalf Of Biogen, Inc. Investors
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.